Aviance Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Aviance Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,000	Closed	-$1.03M	–	235
2018 Q1	$1.03M	Hold	3,000	–	–	0.31%	90
2017 Q4	$1.13M	Hold	3,000	–	–	0.37%	73
2017 Q3	$1.34M	Hold	3,000	–	–	0.45%	60
2017 Q2	$1.47M	Hold	3,000	–	–	0.47%	58
2017 Q1	$1.16M	Hold	3,000	–	–	0.42%	69
2016 Q4	$1.1M	Hold	3,000	–	–	0.39%	74
2016 Q3	$1.21M	Hold	3,000	–	–	0.43%	67
2016 Q2	$1.05M	Hold	3,000	–	–	0.39%	74
2016 Q1	$1.08M	Hold	3,000	–	–	0.38%	71
2015 Q4	$1.63M	Hold	3,000	–	–	0.56%	44
2015 Q3	$1.4M	Hold	3,000	–	–	0.57%	50
2015 Q2	$1.53M	Hold	3,000	–	–	0.57%	44
2015 Q1	$1.35M	Hold	3,000	–	–	0.5%	49
2014 Q4	$1.23M	Hold	3,000	–	–	0.46%	58
2014 Q3	$1.08M	Hold	3,000	–	–	0.41%	62
2014 Q2	$847K	Hold	3,000	–	–	0.33%	94
2014 Q1	$901K	Hold	3,000	–	–	0.38%	74
2013 Q4	$826K	Hold	3,000	–	–	0.35%	77
2013 Q3	$939K	Hold	3,000	–	–	0.44%	61
2013 Q2	$675K	Buy	+3,000	New	+$699K	0.36%	81

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Aviance Capital Partners's REGN Position: Q2 2018 in Review

Aviance Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 3,000 shares — an estimated $1.03M sold.

Aviance Capital Partners first reported a position in REGN in Q2 2013 and held it in 20 quarters. The position peaked at $1.63M in Q4 2015. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

Aviance Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Aviance Capital Partners sold 3,000 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $1.03M.
Aviance Capital Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 20 quarters.
Aviance Capital Partners's Regeneron Pharmaceuticals position peaked at $1.63M in Q4 2015.
624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Aviance Capital Partners's 13F filing for Q2 2018, filed 10 Aug 2018.